FDA programs — Breakthrough Therapy, RMAT, Fast Track, accelerated approval — that speed a promising drug's development. They accelerate review and interaction; none is an approval.
The FDA hands these tools out readily to promising programs: Breakthrough Therapy and Fast Track mean more frequent agency interaction and rolling review; RMAT (Regenerative Medicine Advanced Therapy) is the cell-and-gene-therapy analog; accelerated approval allows a surrogate endpoint with confirmatory follow-up. Europe's equivalent early-support track is the EMA's PRIME scheme.
For reading the digest: a designation is a signal of promise and faster process, not a verdict on efficacy. The lead neoantigen-vaccine program (Moderna/Merck's mRNA-4157/V940) holds Breakthrough Therapy designation, but the category's real test remains a randomized phase 3 with a clinical-benefit endpoint. Don't mistake a designation headline for an approval.